marketcaparena
Search

    MCK

    MCKESSON CORP

    Company overview

    Market capitalization
    $99.84B
    Employees
    41,600
    Latest publication
    2026-09-29
    About MCKESSON CORP

    McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20272026-06-30 · USDQ3 20212020-12-31 · USDQ4 20172017-03-31 · USDQ1 20142013-06-30 · USDQ4 20132013-03-31 · USDQ3 20132012-12-31 · USDQ2 20132012-09-30 · USDQ1 20132012-06-30 · USD
    Total Revenue105,380,000,000USD62,599,000,000USD48,713,000,000USD32,208,000,000USD30,620,000,000USD31,187,000,000USD29,850,000,000USD30,798,000,000USD
    Cost Of Revenue101,695,000,000USD59,592,000,000USD46,024,000,000USD30,288,000,000USD28,624,000,000USD29,519,000,000USD28,130,000,000USD29,198,000,000USD
    Gross Profit3,685,000,000USD3,007,000,000USD2,689,000,000USD1,920,000,000USD1,996,000,000USD1,668,000,000USD1,720,000,000USD1,600,000,000USD
    Selling General Administrative2,264,000,000USD2,291,000,000USD1,664,000,000USD1,258,000,000USD864,000,000USD1,183,000,000USD1,065,000,000USD1,086,000,000USD
    Total Operating Expenses2,366,000,000USD2,113,000,000USD1,977,000,000USD1,258,000,000USD1,344,000,000USD1,183,000,000USD1,065,000,000USD1,005,000,000USD
    Operating Income1,319,000,000USD894,000,000USD712,000,000USD647,000,000USD640,000,000USD485,000,000USD611,000,000USD579,000,000USD
    Total Other Income Expense Net-11,000,000USD-8,257,000,000USD3,962,000,000USD-53,000,000USD-254,000,000USD-49,000,000USD-45,000,000USD-45,000,000USD
    Interest Expense77,000,000USD55,000,000USD77,000,000USD59,000,000USD70,000,000USD59,000,000USD55,000,000USD56,000,000USD
    Income Before Tax1,308,000,000USD-7,363,000,000USD4,674,000,000USD594,000,000USD386,000,000USD436,000,000USD566,000,000USD531,000,000USD
    Income Tax Expense276,000,000USD-1,189,000,000USD1,044,000,000USD174,000,000USD127,000,000USD138,000,000USD165,000,000USD151,000,000USD
    Net Income1,032,000,000USD-6,226,000,000USD3,588,000,000USD424,000,000USD259,000,000USD298,000,000USD401,000,000USD380,000,000USD
    Minority Interest418,000,000USD52,000,000USD35,000,000USD0USD0USD0USD0USD0USD
    Net Income Applicable To Common Shares614,000,000USD-6,226,000,000USD3,588,000,000USD424,000,000USD259,000,000USD298,000,000USD401,000,000USD380,000,000USD
    Unclassified Operating Expenses—-178,000,000USD-28,000,000USD—47,000,000USD——-81,000,000USD
    Interest Income—55,000,000USD——————
    Net Interest Income—-55,000,000USD——————
    Tax Provision—-1,189,000,000USD——————
    Net Income From Continuing Ops—-6,174,000,000USD3,630,000,000USD420,000,000USD259,000,000USD298,000,000USD401,000,000USD380,000,000USD
    Ebit—-7,308,000,000USD4,735,000,000USD669,000,000USD456,000,000USD493,000,000USD601,000,000USD569,000,000USD
    Ebitda—-6,989,000,000USD4,982,000,000USD823,000,000USD619,000,000USD639,000,000USD743,000,000USD709,000,000USD
    Depreciation And Amortization—319,000,000USD247,000,000USD154,000,000USD163,000,000USD146,000,000USD142,000,000USD140,000,000USD
    Reconciled Depreciation—227,000,000USD247,000,000USD154,000,000USD163,000,000USD146,000,000USD142,000,000USD140,000,000USD
    Non Operating Income Net Other—54,000,000USD25,000,000USD6,000,000USD-184,000,000USD10,000,000USD10,000,000USD8,000,000USD
    Discontinued Operations—-3,000,000USD-7,000,000USD0USD0USD0USD0USD0USD
    Research Development——341,000,000USD0USD433,000,000USD0USD0USD0USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20172017-03-31 · USDFY 20142014-03-31 · USDFY 20132013-03-31 · USDFY 20122012-03-31 · USDFY 20112011-03-31 · USDFY 20102010-03-31 · USDFY 20092009-03-31 · USDFY 20082008-03-31 · USD
    Total Revenue198,533,000,000USD137,609,000,000USD122,455,000,000USD122,734,000,000USD112,084,000,000USD108,702,000,000USD106,632,000,000USD101,703,000,000USD
    Cost Of Revenue187,845,000,000USD129,571,000,000USD115,704,000,000USD116,307,000,000USD106,093,000,000USD103,021,000,000USD101,249,000,000USD96,703,000,000USD
    Gross Profit10,688,000,000USD8,038,000,000USD6,751,000,000USD6,427,000,000USD5,991,000,000USD5,681,000,000USD5,383,000,000USD5,000,000,000USD
    Research Development341,000,000USD456,000,000USD480,000,000USD440,000,000USD407,000,000USD376,000,000USD364,000,000USD347,000,000USD
    Selling General Administrative7,466,000,000USD5,418,000,000USD2,351,000,000USD3,065,000,000USD2,762,000,000USD2,566,000,000USD3,075,000,000USD3,189,000,000USD
    Unclassified Operating Expenses-476,000,000USD-486,000,000USD1,500,000,000USD542,000,000USD724,000,000USD—222,000,000USD—
    Total Operating Expenses7,331,000,000USD5,388,000,000USD4,331,000,000USD4,047,000,000USD3,893,000,000USD3,671,000,000USD3,661,000,000USD3,522,000,000USD
    Operating Income3,357,000,000USD2,650,000,000USD2,420,000,000USD2,380,000,000USD2,098,000,000USD2,010,000,000USD1,722,000,000USD1,478,000,000USD
    Interest Income29,000,000USD———————
    Interest Expense308,000,000USD257,000,000USD229,000,000USD251,000,000USD197,000,000USD187,000,000USD144,000,000USD142,000,000USD
    Net Interest Income-279,000,000USD———————
    Income Before Tax6,891,000,000USD2,096,000,000USD1,919,000,000USD1,919,000,000USD1,635,000,000USD1,864,000,000USD1,064,000,000USD1,457,000,000USD
    Income Tax Expense1,614,000,000USD742,000,000USD581,000,000USD516,000,000USD505,000,000USD601,000,000USD241,000,000USD468,000,000USD
    Tax Provision1,614,000,000USD———————
    Net Income5,183,000,000USD1,263,000,000USD1,338,000,000USD1,403,000,000USD1,130,000,000USD1,263,000,000USD823,000,000USD990,000,000USD
    Net Income From Continuing Ops5,277,000,000USD1,354,000,000USD1,338,000,000USD1,403,000,000USD1,130,000,000USD1,263,000,000USD——
    Ebit7,199,000,000USD2,353,000,000USD2,148,000,000USD2,170,000,000USD1,832,000,000USD2,051,000,000USD1,208,000,000USD1,599,000,000USD
    Ebitda8,109,000,000USD3,057,000,000USD2,739,000,000USD2,721,000,000USD2,328,000,000USD2,525,000,000USD1,649,000,000USD1,970,000,000USD
    Depreciation And Amortization910,000,000USD704,000,000USD591,000,000USD551,000,000USD496,000,000USD474,000,000USD441,000,000USD371,000,000USD
    Total Other Income Expense Net3,534,000,000USD-554,000,000USD-501,000,000USD-461,000,000USD-463,000,000USD-146,000,000USD-658,000,000USD-21,000,000USD
    Non Operating Income Net Other90,000,000USD32,000,000USD-156,000,000USD21,000,000USD36,000,000USD43,000,000USD——
    Minority Interest83,000,000USD-5,000,000USD——————
    Discontinued Operations-124,000,000USD-96,000,000USD——————
    Net Income Applicable To Common Shares5,070,000,000USD1,263,000,000USD1,338,000,000USD1,403,000,000USD1,202,000,000USD1,263,000,000USD823,000,000USD989,000,000USD
    Selling And Marketing Expenses—————746,000,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20272026-06-30 · USDQ4 20262026-03-31 · USDQ3 20262025-12-31 · USDQ2 20262025-09-30 · USDQ1 20262025-06-30 · USDQ4 20252025-03-31 · USDQ3 20252024-12-31 · USDQ2 20252024-09-30 · USD
    Total Assets88,330,000,000USD82,323,000,000USD84,190,000,000USD84,160,000,000USD81,311,000,000USD75,140,000,000USD71,081,000,000USD72,429,000,000USD
    Cash And Equivalents5,164,000,000USD—2,959,000,000USD4,004,000,000USD2,418,000,000USD5,691,000,000USD1,131,000,000USD2,509,000,000USD
    Total Current Assets62,837,000,000USD57,210,000,000USD59,697,000,000USD59,887,000,000USD56,801,000,000USD55,398,000,000USD51,741,000,000USD53,341,000,000USD
    Other Current Assets1,098,000,000USD1,043,000,000USD1,458,000,000USD1,358,000,000USD1,160,000,000USD1,063,000,000USD942,000,000USD1,386,000,000USD
    Other Non Current Assets5,577,000,000USD———————
    Total Liabilities89,631,000,000USD———————
    Total Current Liabilities70,356,000,000USD67,017,000,000USD68,131,000,000USD68,031,000,000USD64,331,000,000USD61,604,000,000USD58,562,000,000USD58,771,000,000USD
    Other Current Liabilities5,036,000,000USD———————
    Other Non Current Liabilities2,742,000,000USD———————
    Total Stockholder Equity-4,240,000,000USD-2,172,000,000USD-99,000,000USD-578,000,000USD-863,000,000USD-1,694,000,000USD-2,704,000,000USD-2,642,000,000USD
    Total Equity Including Noncontrolling Interest-1,301,000,000USD———————
    Short Long Term Debt1,297,000,000USD1,267,000,000USD1,132,000,000USD1,747,000,000USD1,249,000,000USD1,191,000,000USD3,590,000,000USD53,000,000USD
    Long Term Debt8,432,000,000USD5,259,000,000USD5,425,000,000USD6,011,000,000USD6,528,000,000USD4,463,000,000USD4,422,000,000USD5,691,000,000USD
    Net Receivables30,316,000,000USD27,985,000,000USD28,213,000,000USD28,286,000,000USD28,158,000,000USD25,643,000,000USD25,831,000,000USD25,270,000,000USD
    Inventory26,259,000,000USD24,207,000,000USD27,067,000,000USD26,134,000,000USD25,065,000,000USD23,001,000,000USD23,837,000,000USD24,176,000,000USD
    Property Plant Equipment Net4,625,000,000USD4,726,000,000USD4,690,000,000USD4,618,000,000USD4,742,000,000USD4,284,000,000USD4,155,000,000USD3,856,000,000USD
    Goodwill11,278,000,000USD———————
    Intangible Assets4,013,000,000USD4,079,000,000USD4,179,000,000USD4,220,000,000USD4,272,000,000USD1,464,000,000USD1,509,000,000USD1,573,000,000USD
    Accounts Payable63,731,000,000USD59,973,000,000USD60,683,000,000USD60,938,000,000USD57,861,000,000USD55,330,000,000USD49,689,000,000USD53,317,000,000USD
    Common Stock3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD
    Retained Earnings22,808,000,000USD22,291,000,000USD20,710,000,000USD19,622,000,000USD18,616,000,000USD17,921,000,000USD16,752,000,000USD15,959,000,000USD
    Accumulated Other Comprehensive Income-749,000,000USD-1,453,000,000USD-903,000,000USD-908,000,000USD-898,000,000USD-932,000,000USD-989,000,000USD-890,000,000USD
    Total Liab—83,157,000,000USD84,289,000,000USD84,738,000,000USD82,174,000,000USD76,834,000,000USD73,785,000,000USD75,071,000,000USD
    Other Current Liab—5,490,000,000USD6,030,000,000USD4,790,000,000USD4,924,000,000USD4,825,000,000USD5,027,000,000USD5,158,000,000USD
    Capital Stock—3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD
    Good Will—11,316,000,000USD11,324,000,000USD11,283,000,000USD11,365,000,000USD10,022,000,000USD10,004,000,000USD10,087,000,000USD
    Cash—3,975,000,000USD2,959,000,000USD4,109,000,000USD2,418,000,000USD5,691,000,000USD1,131,000,000USD2,509,000,000USD
    Cash And Short Term Investments—3,975,000,000USD2,959,000,000USD4,109,000,000USD2,418,000,000USD5,691,000,000USD1,131,000,000USD2,509,000,000USD
    Net Debt—4,639,000,000USD5,665,000,000USD5,683,000,000USD7,515,000,000USD1,699,000,000USD8,626,000,000USD4,710,000,000USD
    Short Term Debt—1,554,000,000USD1,418,000,000USD2,025,000,000USD1,546,000,000USD1,449,000,000USD3,846,000,000USD296,000,000USD
    Short Long Term Debt Total—8,614,000,000USD8,624,000,000USD9,792,000,000USD9,933,000,000USD7,390,000,000USD9,757,000,000USD7,219,000,000USD
    Property Plant Equipment Gross—7,340,000,000USD4,690,000,000USD4,618,000,000USD4,742,000,000USD6,813,000,000USD4,155,000,000USD3,856,000,000USD
    Common Stock Shares Outstanding—122,700,000shares123,700,000shares124,400,000shares125,500,000shares125,900,000shares126,600,000shares129,300,000shares
    Non Current Assets Total—25,113,000,000USD24,493,000,000USD24,273,000,000USD24,510,000,000USD19,742,000,000USD19,340,000,000USD19,088,000,000USD
    Non Current Liabilities Total—16,140,000,000USD16,158,000,000USD16,707,000,000USD17,843,000,000USD15,230,000,000USD15,223,000,000USD16,300,000,000USD
    Non Current Liabilities Other—7,750,000,000USD7,844,000,000USD7,854,000,000USD8,469,000,000USD8,260,000,000USD8,220,000,000USD8,329,000,000USD
    Non Currrent Assets Other—4,725,000,000USD4,053,000,000USD3,983,000,000USD4,131,000,000USD3,972,000,000USD3,672,000,000USD3,572,000,000USD
    Net Working Capital—-9,807,000,000USD-8,434,000,000USD-8,144,000,000USD-7,530,000,000USD-6,206,000,000USD-6,821,000,000USD-5,430,000,000USD
    Unclassified Non Current Assets—267,000,000USD-3,861,000,000USD-3,864,000,000USD-4,063,000,000USD-3,869,000,000USD-3,486,000,000USD-3,397,000,000USD
    Unclassified Current Liabilities—-1,267,000,000USD-1,132,000,000USD-1,469,000,000USD-1,249,000,000USD-1,191,000,000USD-3,590,000,000USD—
    Unclassified Non Current Liabilities—3,131,000,000USD2,889,000,000USD2,842,000,000USD2,846,000,000USD2,507,000,000USD2,581,000,000USD2,280,000,000USD
    Unclassified Equity—-23,016,000,000USD-19,912,000,000USD-19,298,000,000USD-18,587,000,000USD-18,689,000,000USD-18,473,000,000USD-17,717,000,000USD
    Other Assets——4,108,000,000USD4,033,000,000USD4,063,000,000USD3,869,000,000USD3,486,000,000USD3,397,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-03-31 · USDFY 20252025-03-31 · USDFY 20242024-03-31 · USDFY 20232023-03-31 · USDFY 20222022-03-31 · USDFY 20212021-03-31 · USDFY 20202020-03-31 · USDFY 20192019-03-31 · USD
    Total Assets82,323,000,000USD75,140,000,000USD67,443,000,000USD62,320,000,000USD63,298,000,000USD65,015,000,000USD61,247,000,000USD59,672,000,000USD
    Intangible Assets4,079,000,000USD1,464,000,000USD2,110,000,000USD2,277,000,000USD2,059,000,000USD2,878,000,000USD3,156,000,000USD3,689,000,000USD
    Other Current Assets1,043,000,000USD1,063,000,000USD626,000,000USD513,000,000USD5,414,000,000USD677,000,000USD1,523,000,000USD529,000,000USD
    Total Liab83,157,000,000USD76,834,000,000USD69,042,000,000USD63,810,000,000USD65,090,000,000USD63,569,000,000USD54,536,000,000USD49,992,000,000USD
    Total Stockholder Equity-2,172,000,000USD-1,694,000,000USD-1,599,000,000USD-1,490,000,000USD-1,792,000,000USD1,446,000,000USD6,711,000,000USD9,680,000,000USD
    Other Current Liab5,490,000,000USD4,825,000,000USD4,915,000,000USD4,200,000,000USD9,284,000,000USD3,996,000,000USD4,023,000,000USD3,443,000,000USD
    Common Stock3,000,000USD3,000,000USD3,000,000USD3,000,000USD2,000,000USD2,000,000USD2,000,000USD3,000,000USD
    Capital Stock3,000,000USD3,000,000USD3,000,000USD3,000,000USD2,000,000USD2,000,000USD2,000,000USD3,000,000USD
    Retained Earnings22,291,000,000USD17,921,000,000USD14,978,000,000USD12,295,000,000USD9,030,000,000USD8,202,000,000USD13,022,000,000USD12,409,000,000USD
    Good Will11,316,000,000USD10,022,000,000USD10,132,000,000USD9,947,000,000USD9,451,000,000USD9,493,000,000USD9,360,000,000USD9,358,000,000USD
    Cash3,975,000,000USD5,691,000,000USD4,583,000,000USD4,678,000,000USD3,532,000,000USD6,278,000,000USD4,015,000,000USD2,981,000,000USD
    Cash And Short Term Investments3,975,000,000USD5,691,000,000USD4,583,000,000USD4,678,000,000USD3,532,000,000USD6,278,000,000USD4,015,000,000USD2,981,000,000USD
    Total Current Assets57,210,000,000USD55,398,000,000USD47,970,000,000USD44,292,000,000USD46,231,000,000USD45,382,000,000USD42,222,000,000USD38,465,000,000USD
    Total Current Liabilities67,017,000,000USD61,604,000,000USD52,357,000,000USD47,957,000,000USD48,466,000,000USD44,103,000,000USD42,624,000,000USD37,626,000,000USD
    Net Debt4,639,000,000USD1,699,000,000USD2,807,000,000USD2,617,000,000USD4,010,000,000USD3,127,000,000USD5,386,000,000USD4,614,000,000USD
    Short Term Debt1,554,000,000USD1,449,000,000USD345,000,000USD1,267,000,000USD1,096,000,000USD1,132,000,000USD1,406,000,000USD330,000,000USD
    Short Long Term Debt1,267,000,000USD1,191,000,000USD50,000,000USD968,000,000USD799,000,000USD742,000,000USD1,052,000,000USD330,000,000USD
    Short Long Term Debt Total8,614,000,000USD7,390,000,000USD7,390,000,000USD7,295,000,000USD7,542,000,000USD9,405,000,000USD9,401,000,000USD7,595,000,000USD
    Long Term Debt5,259,000,000USD4,463,000,000USD5,579,000,000USD4,626,000,000USD5,080,000,000USD6,406,000,000USD6,335,000,000USD7,265,000,000USD
    Net Receivables27,985,000,000USD25,643,000,000USD21,622,000,000USD19,410,000,000USD18,583,000,000USD19,181,000,000USD19,950,000,000USD18,246,000,000USD
    Inventory24,207,000,000USD23,001,000,000USD21,139,000,000USD19,691,000,000USD18,702,000,000USD19,246,000,000USD16,734,000,000USD16,709,000,000USD
    Accounts Payable59,973,000,000USD55,330,000,000USD47,097,000,000USD42,490,000,000USD38,086,000,000USD38,975,000,000USD37,195,000,000USD33,853,000,000USD
    Property Plant Equipment Net4,726,000,000USD4,284,000,000USD4,045,000,000USD3,812,000,000USD3,640,000,000USD4,681,000,000USD4,251,000,000USD2,548,000,000USD
    Property Plant Equipment Gross7,340,000,000USD6,813,000,000USD6,512,000,000USD3,812,000,000USD3,640,000,000USD4,681,000,000USD4,251,000,000USD2,548,000,000USD
    Accumulated Other Comprehensive Income-1,453,000,000USD-932,000,000USD-881,000,000USD-905,000,000USD-1,534,000,000USD-1,480,000,000USD-1,703,000,000USD-1,849,000,000USD
    Common Stock Shares Outstanding124,100,000shares128,100,000shares134,100,000shares142,200,000shares154,100,000shares160,600,000shares182,000,000shares197,300,000shares
    Non Current Assets Total25,113,000,000USD19,742,000,000USD19,473,000,000USD18,028,000,000USD17,067,000,000USD19,633,000,000USD19,025,000,000USD21,207,000,000USD
    Non Current Liabilities Total16,140,000,000USD15,230,000,000USD16,685,000,000USD15,853,000,000USD16,624,000,000USD19,466,000,000USD11,912,000,000USD12,366,000,000USD
    Non Current Liabilities Other7,750,000,000USD8,260,000,000USD8,723,000,000USD8,438,000,000USD8,760,000,000USD9,782,000,000USD1,662,000,000USD2,103,000,000USD
    Non Currrent Assets Other4,725,000,000USD3,972,000,000USD2,838,000,000USD1,992,000,000USD1,917,000,000USD2,581,000,000USD2,258,000,000USD2,099,000,000USD
    Net Working Capital-9,807,000,000USD-6,206,000,000USD-4,387,000,000USD-3,665,000,000USD-2,235,000,000USD1,279,000,000USD-402,000,000USD839,000,000USD
    Unclassified Non Current Assets267,000,000USD-3,869,000,000USD-2,598,000,000USD-1,755,000,000USD-1,251,000,000USD-2,581,000,000USD-1,858,000,000USD-1,705,000,000USD
    Unclassified Current Liabilities-1,267,000,000USD-1,191,000,000USD—-968,000,000USD-799,000,000USD-4,729,000,000USD-4,392,000,000USD—
    Unclassified Non Current Liabilities3,131,000,000USD2,507,000,000USD2,383,000,000USD-8,406,000,000USD-8,776,000,000USD-9,326,000,000USD-2,257,000,000USD-5,068,000,000USD
    Unclassified Equity-23,016,000,000USD-18,689,000,000USD-15,702,000,000USD-12,886,000,000USD7,753,000,000USD8,390,000,000USD8,280,000,000USD8,016,000,000USD
    Other Assets—3,869,000,000USD2,946,000,000USD1,755,000,000USD1,251,000,000USD2,581,000,000USD1,858,000,000USD1,705,000,000USD
    Cash And Equivalents—5,691,000,000USD4,583,000,000USD4,678,000,000USD3,532,000,000USD6,278,000,000USD4,015,000,000USD2,981,000,000USD
    Current Deferred Revenue——1,000,000USD——3,987,000,000USD3,340,000,000USD—
    Deferred Long Term Liab———1,387,000,000USD1,418,000,000USD1,411,000,000USD2,255,000,000USD2,998,000,000USD
    Other Liab———9,808,000,000USD10,142,000,000USD11,193,000,000USD3,917,000,000USD5,068,000,000USD
    Net Tangible Assets———-12,679,000,000USD-12,416,000,000USD-9,254,000,000USD-4,362,000,000USD-3,560,000,000USD
    Short Term Investments————31,000,000USD———
    Treasury Stock————-17,045,000,000USD-13,670,000,000USD-12,892,000,000USD-8,902,000,000USD
    Long Term Investments——————0USD3,513,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20272026-06-30 · USDQ4 20262026-03-31 · USDQ3 20262025-12-31 · USDQ2 20262025-09-30 · USDQ1 20262025-06-30 · USDQ4 20252025-03-31 · USDQ3 20252024-12-31 · USDQ2 20252024-09-30 · USD
    Net Income1,032,000,000USD1,682,000,000USD1,250,000,000USD1,210,000,000USD784,000,000USD1,306,000,000USD928,000,000USD287,000,000USD
    Depreciation69,000,000USD196,000,000USD65,000,000USD-33,000,000USD157,000,000USD151,000,000USD153,000,000USD163,000,000USD
    Deferred Income Tax19,000,000USD———————
    Other Non Cash Items76,000,000USD-263,000,000USD52,000,000USD129,000,000USD382,000,000USD-104,000,000USD696,000,000USD275,000,000USD
    Unclassified Operating Cash Flow276,000,000USD222,000,000USD49,000,000USD-33,000,000USD—-260,000,000USD25,000,000USD97,000,000USD
    Change To Account Receivables-2,374,000,000USD131,000,000USD166,000,000USD-207,000,000USD-2,089,000,000USD129,000,000USD-565,000,000USD-1,398,000,000USD
    Change To Inventory-2,074,000,000USD3,016,000,000USD-899,000,000USD-1,228,000,000USD-1,971,000,000USD864,000,000USD176,000,000USD1,132,000,000USD
    Change To Liabilities2,756,000,000USD———————
    Change In Working Capital-1,692,000,000USD1,584,000,000USD-184,000,000USD1,147,000,000USD-2,233,000,000USD6,655,000,000USD-4,185,000,000USD1,278,000,000USD
    Operating Cash Flow-220,000,000USD———————
    Capital Expenditures-112,000,000USD-111,000,000USD-108,000,000USD111,000,000USD-111,000,000USD-278,000,000USD-196,000,000USD-218,000,000USD
    Other Investing Activities-71,000,000USD———————
    Unclassified Investing Cash Flow-31,000,000USD615,000,000USD89,000,000USD116,000,000USD131,000,000USD408,000,000USD194,000,000USD370,000,000USD
    Investing Cash Flow-214,000,000USD———————
    Net Debt Issuance3,214,000,000USD———————
    Common Stock Issuance23,000,000USD———————
    Net Common Stock Issuance-2,530,000,000USD———————
    Common Dividends Paid-102,000,000USD———————
    Other Financing Activities-211,000,000USD———————
    Unclassified Financing Cash Flow1,238,000,000USD——-174,000,000USD22,000,000USD—19,000,000USD32,000,000USD
    Financing Cash Flow1,632,000,000USD———————
    Effect Of Forex Changes On Cash-10,000,000USD———————
    Change In Cash1,188,000,000USD1,015,000,000USD-1,056,000,000USD1,426,000,000USD-3,273,000,000USD4,674,000,000USD-1,229,000,000USD207,000,000USD
    End Cash Flow5,256,000,000USD———————
    Total Cash From Operating Activities—3,421,000,000USD1,232,000,000USD2,420,000,000USD-918,000,000USD7,748,000,000USD-2,383,000,000USD2,100,000,000USD
    Free Cash Flow—3,310,000,000USD1,124,000,000USD2,531,000,000USD-1,029,000,000USD7,470,000,000USD-2,579,000,000USD1,882,000,000USD
    Total Cashflows From Investing Activities—425,000,000USD-269,000,000USD-24,000,000USD-3,564,000,000USD-224,000,000USD-136,000,000USD-286,000,000USD
    Net Borrowings—-8,000,000USD-1,197,000,000USD-2,000,000USD1,990,000,000USD-2,434,000,000USD2,416,000,000USD-3,000,000USD
    Total Cash From Financing Activities—-2,820,000,000USD-2,026,000,000USD-961,000,000USD1,176,000,000USD-2,855,000,000USD1,298,000,000USD-1,599,000,000USD
    Dividends Paid—-101,000,000USD-101,000,000USD-89,000,000USD-90,000,000USD-91,000,000USD-92,000,000USD-80,000,000USD
    Sale Purchase Of Stock—-2,671,000,000USD-680,000,000USD581,000,000USD-581,000,000USD-300,000,000USD-827,000,000USD-1,492,000,000USD
    Issuance Of Capital Stock—24,000,000USD15,000,000USD28,000,000USD22,000,000USD28,000,000USD19,000,000USD32,000,000USD
    Begin Period Cash Flow—3,053,000,000USD4,109,000,000USD2,683,000,000USD5,956,000,000USD1,282,000,000USD2,511,000,000USD2,302,000,000USD
    End Period Cash Flow—4,068,000,000USD3,053,000,000USD4,109,000,000USD2,683,000,000USD5,956,000,000USD1,282,000,000USD2,511,000,000USD
    Other Cashflows From Investing Activities—-79,000,000USD-250,000,000USD-227,000,000USD-20,000,000USD-130,000,000USD2,000,000USD-152,000,000USD
    Other Cashflows From Financing Activities—-64,000,000USD-63,000,000USD-1,277,000,000USD-165,000,000USD-58,000,000USD-218,000,000USD-56,000,000USD
    Investments———-24,000,000USD-3,564,000,000USD-224,000,000USD-136,000,000USD-286,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-03-31 · USDFY 20252025-03-31 · USDFY 20242024-03-31 · USDFY 20232023-03-31 · USDFY 20222022-03-31 · USDFY 20212021-03-31 · USDFY 20202020-03-31 · USDFY 20192019-03-31 · USD
    Net Income4,762,000,000USD3,481,000,000USD3,160,000,000USD3,722,000,000USD1,287,000,000USD-4,340,000,000USD1,120,000,000USD33,000,000USD
    Depreciation729,000,000USD636,000,000USD635,000,000USD608,000,000USD760,000,000USD887,000,000USD922,000,000USD949,000,000USD
    Other Non Cash Items272,000,000USD923,000,000USD1,186,000,000USD465,000,000USD2,271,000,000USD484,000,000USD762,000,000USD2,251,000,000USD
    Change To Account Receivables-1,999,000,000USD-3,935,000,000USD-2,954,000,000USD-1,082,000,000USD-1,843,000,000USD1,145,000,000USD-2,494,000,000USD-967,000,000USD
    Change To Inventory-1,082,000,000USD-2,270,000,000USD-1,294,000,000USD-1,259,000,000USD-1,169,000,000USD-2,276,000,000USD-376,000,000USD-368,000,000USD
    Change In Working Capital162,000,000USD1,155,000,000USD-64,000,000USD384,000,000USD82,000,000USD8,186,000,000USD689,000,000USD614,000,000USD
    Total Cash From Operating Activities6,155,000,000USD6,085,000,000USD4,314,000,000USD5,159,000,000USD4,434,000,000USD4,542,000,000USD4,374,000,000USD4,036,000,000USD
    Capital Expenditures-436,000,000USD-859,000,000USD-687,000,000USD-558,000,000USD-535,000,000USD-641,000,000USD-506,000,000USD-557,000,000USD
    Free Cash Flow5,719,000,000USD5,226,000,000USD3,627,000,000USD4,601,000,000USD3,899,000,000USD3,901,000,000USD3,868,000,000USD3,479,000,000USD
    Total Cashflows From Investing Activities-3,432,000,000USD-733,000,000USD-1,072,000,000USD-542,000,000USD-89,000,000USD-415,000,000USD-579,000,000USD-1,381,000,000USD
    Net Borrowings783,000,000USD-21,000,000USD56,000,000USD-277,000,000USD-1,334,000,000USD-540,000,000USD-298,000,000USD-16,000,000USD
    Total Cash From Financing Activities-4,631,000,000USD-3,965,000,000USD-3,342,000,000USD-4,368,000,000USD-6,321,000,000USD-1,693,000,000USD-2,734,000,000USD-2,227,000,000USD
    Dividends Paid-381,000,000USD-345,000,000USD-314,000,000USD-292,000,000USD-277,000,000USD-276,000,000USD-294,000,000USD-292,000,000USD
    Sale Purchase Of Stock-4,750,000,000USD-3,146,000,000USD-3,025,000,000USD-3,638,000,000USD-3,516,000,000USD-770,000,000USD-1,954,000,000USD-1,639,000,000USD
    Issuance Of Capital Stock89,000,000USD101,000,000USD116,000,000USD163,000,000USD220,000,000USD92,000,000USD113,000,000USD75,000,000USD
    Change In Cash-1,981,000,000USD1,371,000,000USD-94,000,000USD743,000,000USD-2,461,000,000USD2,373,000,000USD1,042,000,000USD309,000,000USD
    Begin Period Cash Flow5,956,000,000USD4,585,000,000USD4,679,000,000USD3,935,000,000USD6,396,000,000USD4,023,000,000USD2,981,000,000USD2,672,000,000USD
    End Period Cash Flow3,975,000,000USD5,956,000,000USD4,583,000,000USD4,678,000,000USD3,935,000,000USD6,396,000,000USD4,023,000,000USD2,981,000,000USD
    Other Cashflows From Investing Activities-101,000,000USD-351,000,000USD-416,000,000USD-152,000,000USD299,000,000USD-364,000,000USD-254,000,000USD111,000,000USD
    Other Cashflows From Financing Activities-372,000,000USD-554,000,000USD-175,000,000USD9,123,000,000USD10,092,000,000USD6,624,000,000USD21,136,000,000USD-355,000,000USD
    Unclassified Operating Cash Flow230,000,000USD-110,000,000USD-785,000,000USD-182,000,000USD-127,000,000USD-908,000,000USD-342,000,000USD94,000,000USD
    Unclassified Investing Cash Flow-2,895,000,000USD1,210,000,000USD1,103,000,000USD710,000,000USD236,000,000USD190,000,000USD144,000,000USD446,000,000USD
    Unclassified Financing Cash Flow89,000,000USD101,000,000USD116,000,000USD-9,284,000,000USD-11,286,000,000USD-6,731,000,000USD-21,324,000,000USD75,000,000USD
    Investments—-733,000,000USD-1,072,000,000USD-542,000,000USD-89,000,000USD400,000,000USD37,000,000USD-1,381,000,000USD
    Stock Based Compensation——182,000,000USD162,000,000USD161,000,000USD233,000,000USD1,223,000,000USD95,000,000USD
    Change To Liabilities———4,151,000,000USD3,045,000,000USD1,101,000,000USD3,944,000,000USD1,881,000,000USD
    Cash And Cash Equivalents Changes———249,000,000USD-1,976,000,000USD2,434,000,000USD1,061,000,000USD428,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2027Quarterly · 2026-06-30SegmentMedical Surgical Solutions2,819,000,000USDDisclosure
    Q1 2027Quarterly · 2026-06-30SegmentNorth American Pharmaceutical86,773,000,000USDDisclosure
    Q1 2027Quarterly · 2026-06-30SegmentOncology And Multispecialty14,222,000,000USDDisclosure
    Q1 2027Quarterly · 2026-06-30SegmentPrescription Technology Solutions1,566,000,000USDDisclosure
    FY 2026Yearly · 2026-03-31SegmentMedical Surgical Solutions11,507,000,000USD0000927653-26-000069
    FY 2026Yearly · 2026-03-31SegmentNorth American Pharmaceutical338,252,000,000USD0000927653-26-000069
    FY 2026Yearly · 2026-03-31SegmentOncology And Multispecialty48,423,000,000USD0000927653-26-000069
    FY 2026Yearly · 2026-03-31SegmentPrescription Technology Solutions5,805,000,000USD0000927653-26-000069
    Q3 2026Quarterly · 2025-12-31SegmentMedical Surgical Solutions2,991,000,000USD0000927653-26-000017
    Q3 2026Quarterly · 2025-12-31SegmentNorth American Pharmaceutical88,322,000,000USD0000927653-26-000017
    Q3 2026Quarterly · 2025-12-31SegmentOncology And Multispecialty13,010,000,000USD0000927653-26-000017
    Q3 2026Quarterly · 2025-12-31SegmentOther335,000,000USD0000927653-26-000017
    Q3 2026Quarterly · 2025-12-31SegmentPrescription Technology Solutions1,500,000,000USD0000927653-26-000017
    Q2 2026Quarterly · 2025-09-30SegmentMedical Surgical Solutions2,947,000,000USD0000927653-25-000140
    Q2 2026Quarterly · 2025-09-30SegmentNorth American Pharmaceutical86,481,000,000USD0000927653-25-000140
    Q2 2026Quarterly · 2025-09-30SegmentOncology And Multispecialty12,044,000,000USD0000927653-25-000140
    Q2 2026Quarterly · 2025-09-30SegmentOther302,000,000USD0000927653-25-000140
    Q2 2026Quarterly · 2025-09-30SegmentPrescription Technology Solutions1,376,000,000USD0000927653-25-000140
    Q1 2026Quarterly · 2025-06-30SegmentInternational3,738,000,000USD0000927653-25-000107
    Q1 2026Quarterly · 2025-06-30SegmentMedical Surgical Solutions2,701,000,000USD0000927653-25-000107
    Q1 2026Quarterly · 2025-06-30SegmentPrescription Technology Solutions1,434,000,000USD0000927653-25-000107
    Q1 2026Quarterly · 2025-06-30SegmentUSPharmaceutical89,954,000,000USD0000927653-25-000107
    FY 2025Yearly · 2025-03-31SegmentInternational14,721,000,000USD0000927653-25-000036
    FY 2025Yearly · 2025-03-31SegmentMedical Surgical Solutions11,386,000,000USD0000927653-25-000036
    FY 2025Yearly · 2025-03-31SegmentPrescription Technology Solutions5,216,000,000USD0000927653-25-000036
    FY 2025Yearly · 2025-03-31SegmentU.S.Pharmaceuticaland Specialty Solutions1,100,000,000USD0000927653-25-000036
    FY 2025Yearly · 2025-03-31SegmentUSPharmaceutical327,717,000,000USD0000927653-25-000036
    Q3 2025Quarterly · 2024-12-31SegmentMedical Surgical Solutions2,949,000,000USD0000927653-26-000017
    Q3 2025Quarterly · 2024-12-31SegmentNorth American Pharmaceutical81,198,000,000USD0000927653-26-000017
    Q3 2025Quarterly · 2024-12-31SegmentOncology And Multispecialty9,493,000,000USD0000927653-26-000017
    Q3 2025Quarterly · 2024-12-31SegmentOther283,000,000USD0000927653-26-000017
    Q3 2025Quarterly · 2024-12-31SegmentPrescription Technology Solutions1,371,000,000USD0000927653-26-000017
    Q2 2025Quarterly · 2024-09-30SegmentMedical Surgical Solutions2,946,000,000USD0000927653-25-000140
    Q2 2025Quarterly · 2024-09-30SegmentNorth American Pharmaceutical80,018,000,000USD0000927653-25-000140
    Q2 2025Quarterly · 2024-09-30SegmentOncology And Multispecialty9,157,000,000USD0000927653-25-000140
    Q2 2025Quarterly · 2024-09-30SegmentOther265,000,000USD0000927653-25-000140
    Q2 2025Quarterly · 2024-09-30SegmentPrescription Technology Solutions1,265,000,000USD0000927653-25-000140
    Q1 2025Quarterly · 2024-06-30SegmentInternational3,691,000,000USD0000927653-25-000107
    Q1 2025Quarterly · 2024-06-30SegmentMedical Surgical Solutions2,636,000,000USD0000927653-25-000107
    Q1 2025Quarterly · 2024-06-30SegmentPrescription Technology Solutions1,241,000,000USD0000927653-25-000107
    Q1 2025Quarterly · 2024-06-30SegmentUSPharmaceutical71,715,000,000USD0000927653-25-000107
    FY 2024Yearly · 2024-03-31SegmentMedical Surgical Solutions11,309,000,000USD0000927653-26-000069
    FY 2024Yearly · 2024-03-31SegmentNorth American Pharmaceutical261,368,000,000USD0000927653-26-000069
    FY 2024Yearly · 2024-03-31SegmentOncology And Multispecialty30,490,000,000USD0000927653-26-000069
    FY 2024Yearly · 2024-03-31SegmentOther1,015,000,000USD0000927653-26-000069
    FY 2024Yearly · 2024-03-31SegmentPrescription Technology Solutions4,769,000,000USD0000927653-26-000069
    Q3 2024Quarterly · 2023-12-31SegmentCorporate0USD0000927653-25-000014
    Q3 2024Quarterly · 2023-12-31SegmentInternational3,639,000,000USD0000927653-25-000014
    Q3 2024Quarterly · 2023-12-31SegmentMedical Surgical Solutions3,031,000,000USD0000927653-25-000014
    Q3 2024Quarterly · 2023-12-31SegmentPrescription Technology Solutions1,205,000,000USD0000927653-25-000014
    Q3 2024Quarterly · 2023-12-31SegmentUSPharmaceutical73,023,000,000USD0000927653-25-000014
    FY 2023Yearly · 2023-03-31SegmentInternational20,598,000,000USD0000927653-25-000036
    FY 2023Yearly · 2023-03-31SegmentMedical Surgical Solutions11,110,000,000USD0000927653-25-000036
    FY 2023Yearly · 2023-03-31SegmentPrescription Technology Solutions4,387,000,000USD0000927653-25-000036
    FY 2023Yearly · 2023-03-31SegmentUSPharmaceutical240,616,000,000USD0000927653-25-000036
    FY 2022Yearly · 2022-03-31SegmentInternational36,345,000,000USD0000927653-24-000035
    FY 2022Yearly · 2022-03-31SegmentMedical Surgical Solutions11,608,000,000USD0000927653-24-000035
    FY 2022Yearly · 2022-03-31SegmentPrescription Technology Solutions3,864,000,000USD0000927653-24-000035
    FY 2022Yearly · 2022-03-31SegmentU.S.Pharmaceuticaland Specialty Solutions100,000,000USD0000927653-24-000035
    FY 2022Yearly · 2022-03-31SegmentUSPharmaceutical212,149,000,000USD0000927653-24-000035
    FY 2021Yearly · 2021-03-31SegmentInternational35,965,000,000USD0000927653-23-000038
    FY 2021Yearly · 2021-03-31SegmentMedical Surgical Solutions10,099,000,000USD0000927653-23-000038
    FY 2021Yearly · 2021-03-31SegmentPrescription Technology Solutions2,890,000,000USD0000927653-23-000038
    FY 2021Yearly · 2021-03-31SegmentUSPharmaceutical189,274,000,000USD0000927653-23-000038
    Q1 2021Quarterly · 2020-06-30GeographyInternational8,550,000,000USD0000927653-20-000061
    Q1 2021Quarterly · 2020-06-30GeographyUnited States47,129,000,000USD0000927653-20-000061
    FY 2020Yearly · 2020-03-31SegmentInternational38,341,000,000USD0000927653-22-000051
    FY 2020Yearly · 2020-03-31SegmentMedical Surgical Solutions8,305,000,000USD0000927653-22-000051
    FY 2020Yearly · 2020-03-31SegmentPrescription Technology Solutions2,705,000,000USD0000927653-22-000051
    FY 2020Yearly · 2020-03-31SegmentUSPharmaceutical181,700,000,000USD0000927653-22-000051
    Q4 2020Quarterly · 2020-03-31GeographyInternational9,749,000,000USDLegacy provider
    Q4 2020Quarterly · 2020-03-31GeographyUnited States48,786,000,000USDLegacy provider
    FY 2020Yearly · 2020-03-31GeographyInternational38,342,000,000USD0000927653-20-000033
    FY 2020Yearly · 2020-03-31GeographyUnited States192,709,000,000USD0000927653-20-000033
    Q3 2020Quarterly · 2019-12-31GeographyInternational9,862,000,000USD0000927653-20-000016
    Q3 2020Quarterly · 2019-12-31GeographyUnited States49,310,000,000USD0000927653-20-000016
    Q2 2020Quarterly · 2019-09-30GeographyInternational9,324,000,000USD0000927653-19-000021
    Q2 2020Quarterly · 2019-09-30GeographyUnited States48,292,000,000USD0000927653-19-000021
    Q1 2020Quarterly · 2019-06-30GeographyInternational9,407,000,000USD0000927653-20-000061
    Q1 2020Quarterly · 2019-06-30GeographyUnited States46,321,000,000USD0000927653-20-000061
    FY 2019Yearly · 2019-03-31SegmentInternational38,023,000,000USD0000927653-21-000039
    FY 2019Yearly · 2019-03-31SegmentMedical Surgical Solutions7,618,000,000USD0000927653-21-000039
    FY 2019Yearly · 2019-03-31SegmentPrescription Technology Solutions2,489,000,000USD0000927653-21-000039
    FY 2019Yearly · 2019-03-31SegmentUSPharmaceutical166,189,000,000USD0000927653-21-000039
    Q4 2019Quarterly · 2019-03-31GeographyInternational9,320,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-03-31GeographyUnited States43,109,000,000USDLegacy provider
    FY 2019Yearly · 2019-03-31GeographyInternational38,023,000,000USD0000927653-20-000033
    FY 2019Yearly · 2019-03-31GeographyUnited States176,296,000,000USD0000927653-20-000033
    Q3 2019Quarterly · 2018-12-31GeographyInternational9,685,000,000USD0000927653-20-000016
    Q3 2019Quarterly · 2018-12-31GeographyUnited States46,523,000,000USD0000927653-20-000016
    Q2 2019Quarterly · 2018-09-30GeographyInternational9,301,000,000USD0000927653-19-000021
    Q2 2019Quarterly · 2018-09-30GeographyUnited States43,774,000,000USD0000927653-19-000021
    FY 2018Yearly · 2018-03-31GeographyInternational38,414,000,000USD0000927653-20-000033
    FY 2018Yearly · 2018-03-31GeographyUnited States169,943,000,000USD0000927653-20-000033
    FY 2017Yearly · 2017-03-31GeographyInternational34,105,000,000USD0000927653-19-000009
    FY 2017Yearly · 2017-03-31GeographyUnited States164,428,000,000USD0000927653-19-000009
    FY 2016Yearly · 2016-03-31GeographyInternational32,629,000,000USD0000927653-18-000010
    FY 2016Yearly · 2016-03-31GeographyUnited States158,255,000,000USD0000927653-18-000010
    FY 2015Yearly · 2015-03-31GeographyInternational36,235,000,000USD0000927653-17-000007
    FY 2015Yearly · 2015-03-31GeographyUnited States142,810,000,000USD0000927653-17-000007

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.